Q-omics provides the consensus-scored NDUFA3P4 profile across patient tissues and cancer cell-line models. NDUFA3P4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NDUFA3P4 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, NDUFA3P4 RNA expression shows 10,629 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRC, BRCA, and SARC as cancer lineages where NDUFA3P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA3P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA3P4 survival associations across molecular data types. NDUFA3P4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA3P4 RNA expression–survival associations across cancer types. High NDUFA3P4 expression shows unfavorable associations in KIRC, KIRP and SKCM, but favorable associations in READ, SARC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for NDUFA3P4 RNA expression.
This table summarizes NDUFA3P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFA3P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA3P4 shows lower tumor expression in BRCA and KICH and higher tumor expression in CHOL, LIHC, STAD and BLCA. The BRCA box plot shows higher NDUFA3P4 RNA expression in normal versus tumor tissue (log2 FC = −0.473, t-test p < 0.001).
This table shows molecular features associated with NDUFA3P4 in patient tissues and cancer cell lines. In patient samples, NDUFA3P4 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
